rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3C
|
pubmed:dateCreated |
2003-8-20
|
pubmed:abstractText |
The prognosis of patients with carcinoma of unknown primary remains poor with an expected median survival of 6 to 12 months. We evaluated the activity of a chemotherapy regimen combining gemcitabine and docetaxel in patients who primarily failed cisplatin-based chemotherapy.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2801-4
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:12926116-Adenocarcinoma,
pubmed-meshheading:12926116-Adult,
pubmed-meshheading:12926116-Aged,
pubmed-meshheading:12926116-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12926116-Carcinoma,
pubmed-meshheading:12926116-Carcinoma, Squamous Cell,
pubmed-meshheading:12926116-Cisplatin,
pubmed-meshheading:12926116-Deoxycytidine,
pubmed-meshheading:12926116-Female,
pubmed-meshheading:12926116-Humans,
pubmed-meshheading:12926116-Male,
pubmed-meshheading:12926116-Middle Aged,
pubmed-meshheading:12926116-Neoplasms, Unknown Primary,
pubmed-meshheading:12926116-Paclitaxel,
pubmed-meshheading:12926116-Taxoids,
pubmed-meshheading:12926116-Treatment Failure
|
pubmed:articleTitle |
Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site.
|
pubmed:affiliation |
Centre Régional de Lutte contre le Cancer Val d'Aurelle Montpellier, Parc Euromédecine, 34298-Montpellier, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|